Abstract
OBJECTIVE: Dutch diabetes guidelines have been updated to incorporate specific therapies with cardiovascular and kidney outcomes benefit in type 2 diabetes patients (T2D) at very high risk for cardiorenal complications. This is part of a comprehensive approach to reduce the risk of diabetes-related complications, including management of glycemia, blood pressure, and lipids. The current study examines the prevalence of T2D at very high cardiorenal risk and the deployment of evidence-based approaches to lower this risk. DESIGN: Cross-sectional, observational study. METHOD: A representative population) with T2D in primary care (N= 64,224) was selected from the PHARMO Data Network. A very high risk of CVD was defined as: 1) established CVD, 2) CKD with (very) high cardiovascular risk and 3) heart failure. Drug treatment was determined according to prescriptions in 2019. RESULTS: 25,901 subjects with T2D had a very high risk of CVD (mean age 73.3 years; 42% female). Established CVD, CKD with (very) high cardiovascular risk, and heart failure were observed in 82%, 26% and 22% of patients, respectively. Low-dose salicylates, lipid-lowering and blood pressure-lowering medication were used by 39%, 70% and 69%, respectively. Glucose-lowering medication use included metformin (53%), sulfonylurea-derivatives (24%), and insulin (19%). 2% of the population used a SGLT2 inhibitor or GLP1-receptor agonist. CONCLUSION: 40% of people with DM2 have a very high risk of CVD. Although our findings reflect the recommendations of the previous treatment guideline for DM2, they also show that the new guideline has significant implications for the treatment of a large proportion of people with DM2.
Translated title of the contribution | Prevalence and drug treatment of people with type 2 diabetes mellitus and a very high risk of cardiovascular disease |
---|---|
Original language | Dutch |
Article number | D7569 |
Number of pages | 3 |
Journal | Nederlands Tijdschrift voor Geneeskunde |
Volume | 167 |
Issue number | 1 |
Publication status | Published - 19 Sept 2023 |
Keywords
- Humans
- Female
- Aged
- Male
- Cardiovascular Diseases/epidemiology
- Diabetes Mellitus, Type 2/complications drug therapy epidemiology
- Prevalence
- Cross-Sectional Studies
- Heart Failure/drug therapy epidemiology
- Renal Insufficiency, Chronic/drug therapy epidemiology